[目的]研究人乳腺癌MCF-7/ADM细胞的耐药谱并探讨brca1基因产物表达与该细胞耐药性的相关性。[方法]经MTT法检测MCF-7/ADM细胞的耐药谱;通过免疫荧光法检测brca1基因产物表达情况。[结果]测得MCF-7/ADM细胞对阿霉素的耐药倍数为3.7倍;对长春新碱的耐药倍数为70.3倍;对氟尿嘧啶的耐药倍数为7.8倍。brca1基因产物在MCF-7/ADM细胞中的表达强度(98.23±7.63)高于MCF-7/S细胞(8.69±1.25),差异具有显著性意义(P<0.01)。[结论]MCF-7/ADM细胞是多药耐药细胞株,brca1与肿瘤多药耐药产生可能有一定的相关性。 [Objective] To investigate the drug resistance spectrum of human breast cancer cell line MCF-7 / ADM and to explore the correlation between the expression of brca1 gene product and the cell resistance. [Methods] The drug resistance spectrum of MCF-7 / ADM cells was detected by MTT assay. The expression of brca1 gene product was detected by immunofluorescence assay. [Result] The resistance rate of doxorubicin to MCF-7 / ADM cells was 3.7 times, that of vincristine 70.3 times and that of fluorouracil 7.8 times. The expression level of brca1 gene in MCF-7 / ADM cells was significantly higher than that in MCF-7 / S cells (98.23 ± 7.63) (8.69 ± 1.25) (P <0.01). [Conclusion] MCF-7 / ADM cells are multidrug resistance cell lines, and there may be some correlation between brca1 and multidrug resistance of tumor.